Eganelisib
Code | Size | Price |
---|
TAR-T5432-5mg | 5mg | £104.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5432-1mL | 1 mL * 10 mM (in DMSO) | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5432-10mg | 10mg | £124.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5432-25mg | 25mg | £163.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5432-50mg | 50mg | £229.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T5432-100mg | 100mg | £357.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
IPI-549 is an inhibitor of PI3Kγ (IC50 = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively)
CAS:
1693758-51-8
Formula:
C30H24N8O2
Molecular Weight:
528.576
Pathway:
PI3K/Akt/mTOR signaling
Purity:
0.9956
SMILES:
C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1
Target:
PI3K
References
De Vera AA1, Gupta P.et al.Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.Cancer Lett. 2019 Feb 1;442:91-103
Evans CA, et al. Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-? Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate. ACS Med Chem Lett. 2016 Jul 22;7(9):862-7.
Jiang Y, Xiong W, Jia L, et al. Developing a Na?ve Bayesian Classification Model with PI3K? structural features for virtual screening against PI3K?: Combining molecular docking and pharmacophore based on multiple PI3K? conformations. European Journal of Medicinal Chemistry. 2022: 114824.
Xiong W, Jia L, Liang J, et al. Investigation into the anti-airway inflammatory role of the PI3K? inhibitor JN-PK1: An in vitro and in vivo study. International Immunopharmacology. 2022, 111: 109102
Xiong W, Jia L, Cai Y, et al.Evaluation of the anti-inflammatory effects of PI3K?/? inhibitors for treating acute lung injury.Immunobiology.2023: 152753.
Xiong W, Jia L, Liang J, et al.Investigation into the anti-airway inflammatory role of the PI3K? inhibitor JN-PK1: An in vitro and in vivo study.International Immunopharmacology.2022, 111: 109102.